These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26951840)

  • 1. Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.
    Sato J; Kashiwaba M; Komatsu H; Ishida K; Nihei S; Kudo K
    Jpn J Clin Oncol; 2016 May; 46(5):415-20. PubMed ID: 26951840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
    Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
    Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
    Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
    Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
    BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
    Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
    Ellebaek E; Herrstedt J
    Curr Opin Support Palliat Care; 2008 Mar; 2(1):28-34. PubMed ID: 18685391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
    Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
    Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
    Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
    Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
    JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
    Slimano F; Netzer F; Borget I; Lemare F; Besse B
    Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies.
    Xiao BY; Su T; Huang YJ; Lin GH; Liu ZB; Tang YX; Wang BC
    Support Care Cancer; 2022 Mar; 30(3):2445-2453. PubMed ID: 34775535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer.
    Takala L; Bärlund M; Kellokumpu-Lehtinen PL
    Anticancer Res; 2019 Jan; 39(1):279-283. PubMed ID: 30591469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.
    Abe M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hirashima Y
    Biomed Res Int; 2015; 2015():956785. PubMed ID: 26425564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
    Yokoyama S; Tamaru S; Tamaki S; Nakanishi D; Mori A; Yamakawa T; Ao T; Sakata Y; Mizuno T; Iwamoto T; Watanabe K; Simomura M; Kawakami K; Konishi N; Kageyama S; Ohtani S; Yamada T; Ban S; Ooi K
    Clin Breast Cancer; 2018 Apr; 18(2):e157-e165. PubMed ID: 28735677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
    De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
    Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.